恒瑞医药：子公司获SHR-1894注射液《药物临床试验批准通知书》

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, aimed at treating atopic dermatitis, marking a significant development as no similar drugs have been approved domestically or internationally [1] Company Summary - The company has invested 40.1 million yuan in the SHR-1894 project [1]